Generic immunosuppression in transplantation: current evidence and controversial issues

References

• Global observatory on donation and transplantation. organ donation and transplantation activities. 2012. Available from: http://issuu.com/o-n-t/docs/2012ad [Last accessed 11 January 2015]
   Google Scholar
• Lee RA, Gabardi S. Current trends in immunosuppressive therapies for renal transplant recipients. Am J Health Syst Pharm 2012;69(22):1961-75
   PubMed Web of Science ®Google Scholar
• Patel J, Kobashigawa JA. Minimization of immunosuppression: transplant immunology. Transpl Immunol 2008;20(1-2):48-54
   PubMed Web of Science ®Google Scholar
• RED BOOK Online®.. Available from: http://sites.truvenhealth.com/redbook/index.html [Last accessed 22 January 2015]
   Google Scholar
• Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol 2010;5(7):1305-11
   PubMed Web of Science ®Google Scholar
• Tufts center for the study of drug development. Available from: http://csdd.tufts.edu/ [Last accessed 30 January 2015]
   Google Scholar
• Generic pharmaceutical association. The 2014 Generic drug savings in the U.S. report. Available from: www.gphaonline.org/ [Last accessed 24 January 2015]
   Google Scholar
• Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: Kidney. Am J Transplant 2015;15(Suppl 2):1-34
   PubMed Web of Science ®Google Scholar
• Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003;3(10):1211-15
   PubMed Web of Science ®Google Scholar
• Uber PA, Ross HJ, Zuckermann AO, et al. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J Heart Lung Transplant 2009;28(7):655-60
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77(4):299-311
   PubMed Web of Science ®Google Scholar
• van Gelder T. European society for organ transplantation advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transplant Int 2011;24(12):1135-41
   PubMed Web of Science ®Google Scholar
• Cutler C, Kesselheim A, Gabardi S, et al. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17(3):285-90
   PubMed Web of Science ®Google Scholar
• Harrison JJ, Schiff JR, Coursol CJ, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation 2012;93(7):657-65
   PubMed Web of Science ®Google Scholar
• Ensor CR, Trofe-Clark J, Gabardi S, et al. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy 2011;31(11):1111-29
   PubMed Web of Science ®Google Scholar
• van Gelder T, Gabardi S. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transplant Int 2013;26(8):771-7
   PubMed Web of Science ®Google Scholar
• Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States food and drug administration. Ann Pharmacother 2009;43(10):1583-97
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Approved products with therapeutic equivalence evaluations, 29th ed. Washington, DC: U.S. Department of health and human services, public health service, food and drug administration, center for drug evaluation and research, office of pharmaceutical sciences, office of generic drugs. 2009. Available from: www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm [Last accessed 2 January 2015]
   Google Scholar
• U.S. Food and Drug Administration. Code of federal regulation. Title 21. Food and drugs. Chapter 1. Food and Drug Administration, Department of Health and Human Services. Subchapter D. Drugs for human use. Part 314, Section 314.94. Content and format of an abbreviated application. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.94 [Last accessed 13 January 2015]
   Google Scholar
• Health Canada. Bioequivalence requirements: critical dose drugs. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.php [Last asccessed 13 January 2015]
   Google Scholar
• European medicines agency. Guideline on the investigation of bioequivalence. Available from: www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf [Last accessed 13 January 2015]
   Google Scholar
• U.S. Food and Drug Administration. Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM210930.pdf [Last accessed 13 January 2015]
   Google Scholar
• Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: implications for health-system pharmacists. Am J Health Syst Pharm 2013;70(22):2004-17
   PubMed Web of Science ®Google Scholar
• Generics and biosimilars initiative. Biosimilars approved in Europe. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe [Last accessed 18 January 2015]
   Google Scholar
• Le Meur Y, Borrows R, Pescovitz MD, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the transplantation society consensus meeting. Transplant Rev (Orlando) 2011;25(2):58-64
   PubMedGoogle Scholar
• Pieri M, Miraglia N, Polichetti G, et al. Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. Curr Drug Metab 2011;12(3):253-67
   PubMed Web of Science ®Google Scholar
• de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009;31(4):416-35
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. SangCya (Cyclosporine Oral Solution, USP (MODIFIED)). Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173083.htm [Last accessed 20 January 2015]
   Google Scholar
• Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002;74(7):1013-17
   PubMed Web of Science ®Google Scholar
• Carnahan W, Cooper TY. Neoral-to-Gengraf conversion in renal transplant recipients. Transplant Proc 2003;35(4):1308-13
   PubMed Web of Science ®Google Scholar
• Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005;80(11):1633-5
   PubMed Web of Science ®Google Scholar
• Qazi YA, Forrest A, Tornatore K, Venuto RC. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 2006;20(3):313-17
   PubMed Web of Science ®Google Scholar
• Vitko S, Ferkl M. Interchangeability of cyclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl 2010(115):S12-16
   Google Scholar
• Kraeuter M, Helmschrott M, Erbel C, et al. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Des Devel Ther 2013;7:1421-6
   PubMed Web of Science ®Google Scholar
• Modern medicine network. First-time generic drug approval, September 2009: Tacrolimus capsules. Available from: http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/first-time-generic-drug-approval-september-200?page=full [Last accessed 22 January 2015]
   Google Scholar
• McDevitt-Potter LM, Sadaka B, Tichy EM, et al. A multicenter experience with generic tacrolimus conversion. Transplantation 2011;92(6):653-7
   PubMed Web of Science ®Google Scholar
• Momper JD, Ridenour TA, Schonder KS, et al. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011;11(9):1861-7
   PubMed Web of Science ®Google Scholar
• Rosenborg S, Nordstrom A, Almquist T, et al. Systematic conversion to generic tacrolimus in stable kidney transplant recipients. Clin Kidney J 2014;7(2):151-5
   PubMedGoogle Scholar
• Heavner MS, Tichy EM, Yazdi M, et al. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. Am J Health Syst Pharm 2013;70(17):1507-12
   PubMed Web of Science ®Google Scholar
• Spence MM, Nguyen LM, Hui RL, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012;32(11):981-7
   PubMed Web of Science ®Google Scholar
• Alloway RR, Sadaka B, Trofe-Clark J, et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012;12(10):2825-31
   PubMed Web of Science ®Google Scholar
• Bloom RD, Trofe-Clark J, Wiland A, Alloway RR. A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. Clin Transplant 2013;27(6):E685-93
   PubMed Web of Science ®Google Scholar
• Abdulnour HA, Araya CE, Dharnidharka VR. Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr Transplant 2010;14(8):1007-11
   PubMed Web of Science ®Google Scholar
• Dannhorn E, Cheung M, Rodrigues S, et al. De novo use of generic tacrolimus in liver transplantation - a single center experience with one-yr follow-up. Clin Transplant 2014;28(12):1349-57
   PubMed Web of Science ®Google Scholar
• Robertsen I, Asberg A, Ingerø AO, et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. Transplantation 2015;99(3):528-32
   PubMed Web of Science ®Google Scholar
• van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68(2):261-6
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann G, Reinke P, Rath T, et al. Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. Transplant Int 2012;25(6):680-6
   PubMed Web of Science ®Google Scholar
• Rutkowski B, Bzoma B, Debska-Slizien A, Chamienia A. Generic formulation of mycophenolate mofetil (Myfenax) in de novo renal transplant recipients: results of 12-month observation. Transplant Proc 2014;46(8):2683-8
   PubMed Web of Science ®Google Scholar
• Videla C, Godoy C. Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. Transplant Proc 2007;39(3):602-5
   PubMed Web of Science ®Google Scholar
• Abdallah TB, Ounissi M, Cherif M, et al. The role of generics in kidney transplant: mycophenolate mofetil 500 versus mycophenolate: 2-year results. Exp Clin Transplant 2010;8(4):292-6
   PubMed Web of Science ®Google Scholar
• Namgoong JM, Hwang S, Ahn CS, et al. A pilot study on the safety and efficacy of generic mycophenolate agent as conversion maintenance therapy in stable liver transplant recipients. Transplant Proc 2013;45(8):3035-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martinez F, Orihuela S, Orihuela N, et al. Descriptive retrospective comparative study between two brands of mycophenolate mofetil used in Uruguay: innovator versus generic (Suprimun). Transplant Proc 2014;46(9):2996-9
   PubMed Web of Science ®Google Scholar
• Kim JM, Kwon CH, Yun IJ, et al. A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients. Ann Surg Treat Res 2014;86(4):192-8
   PubMed Web of Science ®Google Scholar
• Esquivel A, Gonzalez-Ramirez R, Alberu J, et al. Comparison of dissolution properties of 2 enteric-coated formulations containing mycophenolate sodium: myfortic vs Femulan. Transplant Proc 2010;42(1):353-6
   PubMed Web of Science ®Google Scholar
• Haroldson JA, Somerville KT, Carlson S, et al. A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients. J Heart Lung Transplant 2001;20(3):372-4
   PubMed Web of Science ®Google Scholar
• Huang MZ, Chen JC, Hu XJ, et al. Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2013;51(10):816-22
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Available from: www.accessdata.fda.gov/scripts/cder/ob/default.cfm [Last accessed 11 January 2015]
   Google Scholar
• ClinicalTrials.gov. Conversion from brand to generic tacrolimus in high risk transplant recipients. Available from: https://clinicaltrials.gov/ct2/show/NCT02014103?term=tacrolimus&recr=Open&rank=5 [Last accessed 27 January 2015]
   Google Scholar
• Al Ameri MN, Whittaker C, Tucker A, et al. A survey to determine the views of renal transplant patients on generic substitution in the UK. Transplant Int 2011;24(8):770-9
   PubMed Web of Science ®Google Scholar
• Hulbert AL, Pilch NA, Taber DJ, et al. Generic immunosuppression: deciphering the message our patients are receiving. Ann Pharmacother 2012;46(5):671-7
   PubMed Web of Science ®Google Scholar